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A B S T R A C T
Acute myeloid leukemia (AML) is a heterogeneous disease characterized by myeloid precursor prolifer-
ation in the bonemarrow, apoptosis reduction and differentiation arrest. Although there are several studies
in this ﬁeld, events related to disease initiation and progression remain unknown. The malignant trans-
formation of hematopoietic stem cells (HSC) is thought to generate leukemic stem cells, and this
transformation could be related to changes in mesenchymal stromal cell (hMSC) signaling. Thus, the aim
of this work was to analyze the gene expression proﬁle of hMSC from AML patients (hMSC-AML) com-
pared to healthy donors hMSCs (hMSC-HD). The results showed a common molecular signature for all
hMSC-AML. Other assays were performed with a large number of patients and the results conﬁrmed a
molecular signature that is capable of distinguishing hMSC-AML from hMSC-HD. Moreover, CCL2 and BMP4
genes encode secreted proteins that could affect HSCs. To verify whether these proteins are differen-
tially expressed in AML patients, ELISA was performed with plasma samples. CCL2 and BMP4 proteins
are differentially expressed in AML patients, indicating changes in hMSC-AML signaling. Altogether, hMSCs-
AML signaling alterations could be an important factor in the leukemic transformation process.
© 2015 Elsevier Ireland Ltd. All rights reserved.
Introduction
Acute myeloid leukemia (AML) is a heterogeneous clonal disor-
der of hematopoietic progenitor cells characterized by myeloid
precursor proliferation and accumulation in the bonemarrow, apop-
tosis reduction and dysfunctional differentiation [1].
The malignant alteration of hematopoietic stem cells leads to a
loss of normal hematopoietic function, which, if left untreated, leads
to death within weeks to months of its clinical presentation [2].
The French, American andBritish group of leukemia experts (FAB)
divided acute myeloid leukemia into eight subtypes based on the
type of cell from which the leukemia developed and based on the
level ofmaturation. Currently, theWorldHealthOrganization (WHO)
provides a classiﬁcation system in which morphology, cytogenetic,
molecular genetics and immunological markers are related [3].
The cellular and molecular basis for the heterogeneity of AML
represents a fundamental problem that has interested cancer re-
searchers. Although several studies have examined this problem,
the events related to the AML initiation and progression remain
unclear.
Themalignant transformation of normal hematopoietic stem cells
(HSCs) is believed to generate leukemic stem cells (LSCs). Similar
to normal HSCs, LSCs are characterized by their self-renewal ability,
repopulating potential and progeny cell production. LSCs have also
been reported to express stem cell markers and to survive indeﬁ-
nitely upon serial transplantations in animal models [4].
Transforming events could occur in a HSC, and one of the con-
sequences of this event is the inability of this stem cell to generate
normal progenitors and mature blood cells, thus generating its ma-
lignant counterpart, the LSC. The similar cell surface phenotypes of
LSCs and HSCs support the idea that primitive cells are the origin cells
for AML regardless of the maturation state of leukemia blasts [5].
Lapidot and co-workers described the existence of LSCs for AML.
The engraftment of human LSC preparations into xenogeneic trans-
plantation models has been regarded as evidence of the presence
of leukemia-initiating cells for human AML [6].
The concept that the tumor cells present stem cell properties
implies that LSC arises as an intrinsic property of tumor biology and
development. However, the surrounding microenvironment includ-
ing ﬁbroblasts, adipocytes, endothelial cells, and the extracellular
matrix play important roles in cancer progression [7]. The direct
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contact among stem cells and their niches is essential in regulat-
ing asymmetric divisions and promoting stem cell renewal [6].
HSCs reside in two distinct niches: the endosteal and the vas-
cular. Signals from cells in these niches provide the clues for
quiescence, self-renewal, survival and fate speciﬁcation of these cells.
Recent studies have shown that spatially distinct vascular niches
for quiescent and nonquiescent HSCs are present in the bonemarrow
[8]. Although LSCs have similar microenvironment, it has been re-
ported its expansion at hypoxic bone marrow areas in endosteal
niche [9], contrary to what happens with HSCs that in hypoxic con-
ditions are maintained in a quiescent state. Thus, the malignant
transformation that generates LSCs could be related to changes in
some niche component signaling.
LSCs localize and associate with cells around the endosteum to
form discrete niches. Other cell types, including mesenchymal
stromal cells (MSCs), which contribute to this niche, play a major
role in LSC biology [10].
It is suggested that genetic changes in bonemarrow stromal cells
are not trivial because they are able to differentiate into osteolineage
progenitors (osteoblast precursors) and initiate a malignant process
in the normal HSC endosteal niche [10].
In this context, the aim of this work was to analyze the proﬁle
of humanmesenchymal stromal cells (hMSCs) in acute myeloid leu-
kemia patients. To address this hypothesis, we used chip arrays to
evaluate the gene expression proﬁles of hMSCs from AML patients
(hMSC-AML) compared to the proﬁles of hMSCs from healthy donors
(hMSC-HD). The results showed that a common molecular signa-
ture exists for all hMSCs-AML compared to hMSCs-HD and that some
of the genes that were differentially expressed could be related to
malignant transformation.
Materials and methods
Patient and donor samples
Bonemarrow (BM)-derived samples were obtained from patients diagnosed with
acute myeloid leukemia (without any treatment) and from healthy donors. The 33
samples obtained from AML patients were morphologically characterized by
immunophenotype as shown in Table 1. BM aspirates from AML patients were ob-
tained from 19male patients (mean age: 36.9; age range: 14–78 years) and 14 female
patients (mean age: 40.8; age range 9–70) years. These patients were stratiﬁed into
four cohorts: chip array cohort (n = 7), unsupervised chip array cohort (n = 10),
RT-qPCR cohort (n = 19) and ELISA cohort (n = 33) (Table 1). All samples were pro-
vided from different hospitals of Rio de Janeiro and other states in Brazil. As control,
we used 13 samples obtained from healthy donors that were registered at the Bone
Marrow Transplantation Unit, National Cancer Institute (Rio de Janeiro, Brazil). BM
aspirates from healthy donors were obtained from 5 male donors (mean age: 40.3
years; age range 30–59 years) and 8 female donors (mean age: 40.4 years; age range:
32–47 years). All samples were obtained in accordance with the guidelines of the
local Ethics Committee and the Helsinki Declaration. This study was approved by
the National Cancer Institute Ethics Committee (no. 034/06) and all participants signed
informed consent forms.
Isolation and culture of human BM-derived mesenchymal stromal cells (hMSCs)
Bone marrow samples from AML patients and healthy donors were centri-
fuged at 1200 rpm for 15min. After the samples were centrifuged, plasma from each
sample was collected, treated with 1 μL/mL protease inhibitor mix (GE Healthcare
Life Sciences, PA, USA) and frozen at −70 °C.
The precipitates obtained after BM centrifugation were plated in non-coated
25-cm2 polystyrene culture ﬂasks (TPP, Switzerland) in low-glucose Dulbecco’s modi-
ﬁed Eagle’s medium (DMEM-LG, InvitrogenTM, CA, USA) supplemented with 10% fetal
bovine serum (FBS, Hyclone, USA), 100 IU/mL penicillin, 100 μg/mL streptomycin
(InvitrogenTM, CA, USA), and 2 mM l-glutamine (InvitrogenTM, CA, USA). The cells
were cultured at 37 °C in a humidiﬁed atmosphere of 5% CO2.
After the cells were cultured for one week, non-adherent cells were removed
from the culture ﬂask, and the medium was changed twice a week until the cul-
Table 1
List of AML patients that participated in this study.
Laboratory code FAB subtype %Blasts Sex Age Chip array cohort
AML samples
Unsupervised chip
array cohort AML samples
RT-qPCR cohort
AML samples
ELISA cohort
AML samples
005/12 M4/M5 80% Male 43 x x x x
006/12 M3 85% Male 68 x x x x
007/12 M1/M2 75% Female 9 x x x x
009/12 M3 80% Male 30 x
010/12 M1/M2 36% Male 18 x x x
011/12 M1/M2 64% Female 13 x x
012/12 M1/M2 60% Female 13 x x x x
017/12 M0 40% Female 62 x
002/13 M1 29% Female 70 x
007/13 M2 23% Male 14 x
008/13 M2 98% Male 42 x x x x
009/13 M2 56% Male 30 x x x x
010/13 M2 38% Male 25 x x
017/13 M3 71.80% Female 21 x x
021/13 M4/M5 60% Female 22 x
025/13 M4/M5 75% Male 46 x x x
028/13 M2 17% Male 26 x x
031/13 M2 70% Female 61 x x
036/13 M3 84% Female 29 x x x
037/13 M4/M5 80% Male 35 x x x
040/13 M2 84% Male 28 x
041/13 LMA unclassiﬁed 56% Male 45 x
042/13 LMA unclassiﬁed 90% Male 78 x
043/13 M3 80% Female 53 x
045/13 M3 75% Male 31 x x
047/13 M2 87% Female 47 x
050/13 M2 25% Male 28 x x
051/13 M1 67% Male 50 x x
053/13 M1 90% Male 32 x x
054/13 LMA unclassiﬁed 60% Male 32 x x
056/13 M4/M5 90% Female 60 x
059/13 M3 98% Female 47 x
061/13 M4/M5 84% Female 65 x
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tured hMSCs reached 80% conﬂuence. Then, hMSCs were removed from the plates
by treatment with 0.05% trypsin (InvitrogenTM, CA, USA) for 5 min at 37 °C and then
replated in another culture ﬂask at a density of 2000 cells/cm2 (passage 1). When
80% conﬂuencewas obtained (approximately 7 culture days), the cells were trypsinized
and replated in another fresh culture ﬂask (passage 2). These processes were re-
peated up to passage 3, when hMSCs were used for all experiments.
Conﬁrmation of hMSCs
To conﬁrm the multipotentiality of hMSCs used in this work, experiments were
performed in accordance with the minimal criteria for deﬁning multipotent mes-
enchymal stromal cells as deﬁned by the International Society for Cellular Therapy
[11].
The cultured plastic-adherent cells expressing themarkers CD73 (#561254), CD90
(#561970) and CD105 (#561443) but not expressing the lineage commitmentmarkers
CD14 (# 347493), CD19 (#340951), CD34 (#348057), CD45 (#347463) and HLA-DR
(#349528) (BD Biosciences, CA, USA) were able to differentiate into adipocytes and
osteoblasts.
The ability of hMSC cultures to differentiate into adipocytes and osteoblasts was
also tested at passage 3. To induce adipogenic differentiation, hMSCs were cul-
tured with adipocyte differentiation basal medium (Gibco, CA, USA), and Oil-red-O
(Sigma-Aldrich, MO, USA) was used to detect lipid accumulation. Osteogenic dif-
ferentiation was induced using osteocyte differentiation basal medium (Gibco, CA,
USA). Osteoblasts were identiﬁed by Alizarin Red S (Isofar, Brazil) staining.
Proliferation assay
Cell proliferation was measured using a 4-[3-(4-Iodophenyl)-2-(4-nitrophenyl)-
2H-5-tetrazolio]-1.3-benzene disulfonate (WST-1) assay (Roche, Germany). For this
assay, 6.2 × 102 cells were plated in 96-well microplates. After 48, 96 and 144 h, 3 μL
of WST-1 was added to each well, and the microplates were incubated at 37 °C for
an additional 3 h. Then, the plates were read on a microplate reader (Bio-Rad, model
550, CA, USA) at 450 nm with a reference wavelength at 630 nm. Data analyses and
graphical representations were performed using GraphPad PrismTM software
(GraphPad Software Inc., CA, USA). All experiments were performed in triplicate.
Cell cycle assay
The cell cycle was analyzed using propidium iodide (PI; Sigma-Aldrich, MO, USA)
as described by Nicoletti et al. [12]. The cell cycle was blocked by reducing FBS to
0.1% for 24 h, and then the concentration of FBS was returned to 10%. Three days
later, the cells were harvested for cell cycle analysis. First, the cells were washed
and ﬁxed overnight in cold ethanol (70%). Then, the ﬁxed cells were washed and
reconstituted in 250 μL of buffer (0.1% NP40, 0.2 mg/mL RNase, and 0.2 mg/mL PI)
and incubated for 30 min at 4 °C. Ten thousand events were collected from each
sample using a FACSCalibur ﬂow cytometer (BD Biosciences, CA, USA). All experi-
ments were performed in triplicate. The data were analyzed using CellQuest software
(BD Biosciences, CA, USA).
Expression chip array data analysis
Total RNA from hMSC cultures in passage 3 was obtained using TRIzol reagent
(Invitrogen, CA, USA) and puriﬁed using an RNeasy Mini Kit (Qiagen, CA, USA) ac-
cording to the manufacturer’s instructions. One hundred nanograms (100 ng) of total
RNA was used to synthesize biotinylated cRNA using a GeneChip Whole Transcrip-
tion (WT) Sense Target Labeling Assay Kit (Affymetrix, CA, USA). Then, the biotinylated
cRNA was hybridized to GeneChip Human Gene 1.0 ST Arrays (Affymetrix, CA, USA),
washed and stained according to the manufacturer’s protocols. The GeneChip arrays
were scanned using a GeneChip® Scanner 3000. Affymetrix Expression Console soft-
ware version 1.0 was used to create summarized expression values (CHP-ﬁles), and
the robust multichip analysis (RMA) algorithm was applied. The data were ana-
lyzed using Partek® software (http://www.partek.com) [13], with differentially
expressed genes with a ≥2-fold change used as criteria to deﬁne overexpression or
downregulation. The pathway analysis and related processes were obtained using
MetaCoreTM software (http://thomsonreuters.com/metacore/).
Quantitative PCR (RT-qPCR)
RT-qPCR analyses were performed using two micrograms of mRNA treated with
ampliﬁcation grade DNase I (Invitrogen, CA, USA) and reverse transcribed with Su-
perscript III Reverse transcriptase® (Invitrogen, CA, USA). Each reaction was performed
with 5 μL of SYBR Green PCR Master Mix® (Applied Biosystems, CA, USA), 2.5 μL of
cDNA (10 ng of cDNA) and 2 μM each primer. The quantitative determination of mRNA
levels was performed using Rotor-Gene 6000 Series software (Corbett, Australia).
The reactions were performed in a Rotor-Gene 6000 thermocycler (Corbett, Aus-
tralia) using the following program: 95 °C for 5 min, followed by 45 cycles at 95 °C
for 15 s, with a ﬁnal extension at 62 °C for 40 s. Dissociation curve analysis was used
to demonstrate equal ampliﬁcation eﬃciency of a speciﬁc PCR product for all primers
used in this study; all primers demonstrated equal ampliﬁcation eﬃciency and spe-
ciﬁc PCR products through dissociation curve analysis. The determination of fold
expression change was calculated using the DDCt method according to Livak and
Schmittgen [14]. Expression levels were estimated in triplicate, and B2M and GAPDH
were used as normalization genes. The following primers were used: GAPDH Fw (5′-
GTCAACGGATTTGGTCGTATTG-3′) and Rev (5′-TGGAAGATGGTGATGGGATTT-3′), B2M
Fw (5′-ATGAGTATGCCTGCCGTGTGA-3′) and Rev 5′-CGGCATCTTCAAACCTCCATG-
3′), CCL2 Fw (5′-CCCAGTCACCTGCTGTTAT-3′) and Rev (5′-GGAGTTTGGGTTTGCTTGTC-
3′), SPON2 Fw (5′-GGAAGAACCAGTACGTCAGTAAC-3′) and Rev (5′-GCACCACAAA
CGAGACCA-3′), MMP16 Fw (5′-TATTCGCCGTGCCTTTGAT-3′) and Rev (5′-CCACATC
ACGTTTGCCATTT-3′), CLDN1 Fw (5′-TCTTTGACTCCTTGCTGAATCT-3′) and Rev (5′-
GCCAGACCTGCAAGAAGAAATA-3′), BMP4 Fw (5′-CCATGATTCCTGGTAACCGA-3′) and
Rev (5′-CCTGAATCTCGGCGACTT-3′), and SSP1 Fw (5′-GCTAAACCCTGACCCATCTC-
3′) and Rev (5′-CTACATCATCAGAGTCGTTCGAG-3′). The results were compared
using the Mann–Whitney test. Statistical analysis and graphical representations
were performed using GraphPad PrismTM software (GraphPad Software Inc., CA,
USA).
ELISA
To perform ELISA, we used the bone marrow plasma samples that were collect-
ed previously from AML patients and from healthy donors and stocked at −70 °C.
The levels of BMP4, SSP1 (Sigma-Aldrich, MO, USA) and CCL2 (Peprotech, NJ, USA)
were determined in triplicate using speciﬁc ELISA kits according to the manufac-
turers’ instructions. Statistical analysis and graphical representations were performed
using GraphPad PrismTM software (GraphPad Software Inc., CA, USA).
Statistical analysis
All experiments were carried out in triplicate and the data were expressed as
the mean ± standard error of the mean. The results were compared using an un-
paired Mann–Whitney test and a p-value <0.05 was considered as statistically
signiﬁcant (*p < 0.05, **p < 0.01). Statistical analysis and graphical representations
were performed using GraphPad PrismTM software (GraphPad Software Inc., CA,
USA).
Results
In vitro differentiation potential of hMSC cultures
To determine whether the expanded hMSC cultures main-
tainedmultipotency differentiation characteristics, we tested hMSCs
from AML patients and from healthy donors at passages 3 for dif-
ferentiation into adipogenic and osteogenic cells. hMSCs cultured
in adipogenic medium for 3 weeks showed lipid droplets charac-
teristic of adipogenic cells by Oil Red O staining (Fig. 1C, D).
Osteogenic differentiation was demonstrated by calcium deposi-
tion, which was stained by Alizarin Red S (Fig. 1E, F). Undifferentiated
hMSCs from AML patients and from healthy donors were used as
controls (Fig. 1A, B). Our results showed that hMSC cultures from
both AML patients and healthy donors were able to differentiate into
adipogenic and osteogenic cells that maintained their multipotency
capacity. However, interestingly, while adipogenic differentiation did
not present any differences between both types of hMSC cultures,
osteogenic differentiation presented some differences when com-
paring hMSCs from patients and from healthy donors. As shown in
Fig. 1E and F, while both cultures were able to differentiate into os-
teogenic cells, the hMSC cultures from AML patients presented a
decreased potential for osteogenic differentiation.
hMSCs from AML patients displayed conserved proliferation and cell
cycle proﬁles
To verify whether the hMSC cultures from AML patients pre-
sented changes in their proliferation potential and had cell cycle
arrest, we performed WST and ﬂow cytometry assays, respective-
ly, and compared the results with those of hMSC cultures from
healthy donors. As observed in Fig. 2A and B, the proliferation and
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cell cycle proﬁles were identical for all hMSC cultures; no signiﬁ-
cant alterations were observed. These results indicate that hMSC
cultures conserved their proliferation capacity in the culture instead
of that of the disease.
Fifty-ﬁve genes deﬁne a hMSC-AML molecular proﬁle
Although hMSCs from AML patients conserved their prolifera-
tion proﬁle, the molecular pattern of these cells could differ from
that of hMSCs from healthy donors. Thus, we determined the global
gene expression pattern for hMSC cultures from AML patients and
compared it with the global gene expression pattern for hMSC cul-
tures from healthy donors. We performed a comparative
transcriptome analysis using an expression chip array assay.
In this assay, 7 samples from different AML subtypes were used
and compared with two pools of healthy donors. After the 3rd
passage, total RNA was obtained from each hMSC culture, pro-
cessed, hybridized to GeneChip Human Gene 1.0 ST Arrays
(Affymetrix, CA, USA), washed and stained according to the man-
ufacturer’s protocols. Using a ≥2-fold change as a cut-off to deﬁne
overexpression or downregulation, ﬁfty-ﬁve genes were found to
be differentially expressed in all chip array assays. The hierarchi-
cal clustering of these differentially expressed genes shown in Fig. 3
suggests that a commonmolecular signature exists for all MSCs from
AML patients compared to that for MSCs from healthy donors.
Notably, 11 of these 55 genes were overexpressed in hMSC-AML cul-
tures, while 44 of these genes were downregulated, indicating a
global gene expression decrease in hMSC cultures from AML pa-
tients (Table 2).
In silico analysis of these results using MetaCoreTM software
showed that the genes found altered in hMSCs from AML patients
Fig. 1. hMSC multipotency capacity. (A and B) Undifferentiated hMSCs from healthy donors (HD) and AML patients, respectively (200× magniﬁcation). (C and D) Adipogenic
differentiation of hMSCs from HD and AML patients, respectively. Accumulation of neutral lipid vacuoles stained with oil red O indicate differentiation (200× magniﬁca-
tion). (E and F) Osteogenic differentiation of hMSCs from HD and AML patients, respectively. Calcium deposition stained with alizarin red indicates differentiation (50×
magniﬁcation).
Fig. 2. Cell proliferation and cell cycle analysis. (A) Cell proliferation proﬁles of hMSC-
AML and hMSC-HD were determined after 48, 96 and 144 h of culture by WST-1
assay. (B) Using the same samples, ﬂow cytometry was used to analyze the cell cycle.
The results did not differ among all cultures.
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function in important signaling pathways during normal hemato-
poiesis. These genes are involved primarily in processes of cellular
adhesion, the Osteopontin (SSP1) pathway and the WNT pathway,
among other functions. Both SSP1 andWNT are important signaling
pathways related to HSC maintenance and differentiation, respec-
tively [15,16].
RT-qPCR and unsupervised chip array assay conﬁrmed the molecular
signature of hMSC-AML cultures
To conﬁrm the obtained chip array results, quantitative PCR (RT-
qPCR) of some overexpressed and downregulated genes were
performed. In this case, the analysis was performed with a larger
number of patients with different subtypes (n = 19) andwith healthy
donors (n = 13). The overexpressed genes, i.e., CCL2 and SPON2, and
the downregulated genes, i.e., MMP16, BMP4, CLDN1 and SSP1, in
hMSC-AML cultures were used in this analysis. These genes were
chosen because all of them had been previously described as related
to the microenvironment, HSC or AML. CCL2 and MMP16 were se-
lected because they are related to the bone marrow
microenvironment and to AML [17,18]. BMP4 and SSP1 genes are im-
portant for the development and maintenance of HSCs [15,19], and
SPOND2 and CLDN1 were chosen because they are related to neo-
plasia [20,21]. The RT-qPCR results presented in Fig. 4 conﬁrmed the
obtained chip array assay results.
Furthermore, we performed another chip array assay using 3 ad-
ditional AML patient samples. At this time, an unsupervised analysis
of the 55 differentially expressed genes was performed with these
3 new hMSC samples from AML patients and with the other 7
samples used previously to verify whether the samples could group
into clusters that separate AML patients from healthy donors. As
shown in Fig. 5, these 55 genes were able to distinguish the hMSC-
AML cultures from hMSC-HD cultures.
Secreted proteins from hMSC-AML cultures could be related to
malignant transformation
Changes inMSC signaling could be related to themalignant trans-
formation of HSCs to LSCs. Some of the genes identiﬁed by the chip
array assay are secreted proteins that could affect HSCs. To analyze
whether these secreted proteins are differentially expressed in AML
patients, we performed ELISAwith the bonemarrow plasma samples
from 33 AML patients and from 11 healthy donors. The secreted pro-
teins selected were CCL2, SSP1 and BMP4 (CCL2 is overexpressed
and the others are downregulated in AML patients). The results con-
ﬁrmed the increase in CCL2 protein levels and the decrease in BMP4
protein levels in AML patient bone marrow plasma samples, sug-
gesting that MSC signaling differs between hMSC cultures from
healthy donors and AML patients (Fig. 6A, B). However, no signif-
icant changes were observed for SSP1 protein levels (Fig. 6C). All of
these proteins have been described as important components pro-
duced by the hematopoietic microenvironment that regulates both
HSC number and function. Thus, this modiﬁed signaling could be
related to the malignant transformation of HSCs to LSCs.
Discussion
The BMmicroenvironment is composed of hematopoietic stem
cells (HSCs) and several nonhematopoietic cells types including os-
teoblasts and osteoclasts, sinusoidal endothelial cells, ﬁbroblasts,
reticular cells, mesenchymal stromal cells (MSCs), perivascular
stromal cells, immune cells, and several others which may play a
Fig. 3. Hierarchical clustering of the 55 differentially expressed genes identiﬁed by chip array assay. The results showed a common molecular signature for all hMSCs from
AML patients compared to hMSCs from healthy donors.
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critical role in hematopoiesis and contribute to bone marrow
homeostasis.
Recent studies have highlighted the critical importance of bone
marrow MSCs as essential constituents for the HSC niche through
production of factors such as CXCL12 and SCF [8,9]. Moreover, studies
have provided insights into the role of aberrant microenviron-
ment signaling leading to disease pathology, being MSCs recognized
as an essential element of both healthy and leukemic hematopoi-
etic microenvironment [22].
In AML, studies have provided evidence that proliferation, survival
and drug resistance could be modulated by MSCs from the BM mi-
croenvironment. The signaling between LSCs andMSCs is essential for
leukemia survival and disease progression. However, howMSC signal-
ing could affect the leukemogenic process remains unclear [17,23–25].
In this study, we characterized and compared hMSCs from AML
patients and healthy donors. Our cultures were derived from AML
patients at diagnosis, and when the morphology and proliferation
of these cultures were compared to hMSCs from HD, all hMSCs pre-
sented normal morphologies and proliferation potentials. One
previous study veriﬁed the heterogeneous morphology and diverse
proliferation capacities among AML cultures compared to hMSCs
from HD [26]. These contradictory results could be explained by the
differences in patients between the studies; in contrast to our study,
this work used AML patients that had been previously treated, and
this previous treatment could inﬂuence the morphology and pro-
liferation of hMSC-AML.
One fundamental characteristic of MSCs is their potential
for adipogenic, chondrogenic and osteogenic differentiation.
Table 2
List of the 55 differentially expressed genes identiﬁed by chip array assay.
Gene
symbol
Gene_assignment RefSeq Fold-change AML vs POOL DONORS
NLGN4Y NR_028319 // NLGN4Y // neuroligin 4, Y-linked // Yq11.221 // 22829 /// NM_001164 NR_028319 5.55 AML up vs POOL DONORS
SPON2 NM_012445 // SPON2 // spondin 2, extracellular matrix protein // 4p16.3 // 10417 NM_012445 2.62 AML up vs POOL DONORS
UIMC1 AF284753 // UIMC1 // ubiquitin interaction motif containing 1 // 5q35.2 // 51720 AF284753 2.47 AML up vs POOL DONORS
MUC12 NM_001164462 // MUC12 // mucin 12, cell surface associated // 7q22 // 10071 /// NM_001164462 2.42 AML up vs POOL DONORS
CCL2 NM_002982 // CCL2 // chemokine (C-C motif) ligand 2 // 17q11.2-q12 // 6347 /// E NM_002982 2.31 AML up vs POOL DONORS
RASD1 NM_016084 // RASD1 // RAS, dexamethasone-induced 1 // 17p11.2 // 51655 /// ENST0 NM_016084 2.23 AML up vs POOL DONORS
LGALS3BP NM_005567 // LGALS3BP // lectin, galactoside-binding, soluble, 3 binding protein NM_005567 2.08 AML up vs POOL DONORS
LOC151009 AK095678 // LOC151009 // hypothetical LOC151009 // 2q13 // 151009 /// AK056084 / AK095678 2.06 AML up vs POOL DONORS
RUNDC2C NR_002939 // RUNDC2C // RUN domain containing 2C // 16p11.2 // 440352 /// ENST00 NR_002939 2.04 AML up vs POOL DONORS
TP53I11 NM_001076787 // TP53I11 // tumor protein p53 inducible protein 11 // 11p11.2 // NM_001076787 2.02 AML up vs POOL DONORS
C6orf138 NM_207499 // C6orf138 // chromosome 6 open reading frame 138 // 6p12.3 // 442213 NM_207499 2.01 AML up vs POOL DONORS
EZR NM_003379 // EZR // ezrin // 6q25.3 // 7430 /// NM_001111077 // EZR // ezrin // NM_003379 −2.02 AML down vs POOL DONORS
SH3BGR NM_007341 // SH3BGR // SH3 domain binding glutamic acid-rich protein // 21q22.3 NM_007341 −2.02 AML down vs POOL DONORS
RDH10 NM_172037 // RDH10 // retinol dehydrogenase 10 (all-trans) // 8q21.11 // 157506 NM_172037 −2.03 AML down vs POOL DONORS
IRF6 NM_006147 // IRF6 // interferon regulatory factor 6 // 1q32.3-q41 // 3664 /// EN NM_006147 −2.05 AML down vs POOL DONORS
FRY NM_023037 // FRY // furry homolog (Drosophila) // 13q13.1 // 10129 /// ENST00000 NM_023037 −2.05 AML down vs POOL DONORS
RAP1GDS1 NM_001100426 // RAP1GDS1 // RAP1, GTP-GDP dissociation stimulator 1 // 4q23-q25 NM_001100426 −2.09 AML down vs POOL DONORS
PGM5P2 NR_002836 // PGM5P2 // phosphoglucomutase 5 pseudogene 2 // 9q12 // 595135 /// N NR_002836 −2.11 AML down vs POOL DONORS
MEGF9 NM_001080497 // MEGF9 // multiple EGF-like-domains 9 // 9q32-q33.3 // 1955 /// E NM_001080497 −2.11 AML down vs POOL DONORS
CYFIP2 NM_001037332 // CYFIP2 // cytoplasmic FMR1 interacting protein 2 // 5q33.3 // 26 NM_001037332 −2.11 AML down vs POOL DONORS
NT5DC3 NM_001031701 // NT5DC3 // 5’-nucleotidase domain containing 3 // 12q22-q23.1 // NM_001031701 −2.11 AML down vs POOL DONORS
NCAM1 NM_181351 // NCAM1 // neural cell adhesion molecule 1 // 11q23.1 // 4684 /// NM_ NM_181351 −2.17 AML down vs POOL DONORS
ELN NM_000501 // ELN // elastin // 7q11.23 // 2006 /// NM_001081754 // ELN // elasti NM_000501 −2.18 AML down vs POOL DONORS
MMP16 ENST00000286614 // MMP16 // matrix metallopeptidase 16 (membrane-inserted) // 8q ENST00000286614 −2.25 AML down vs POOL DONORS
SDC2 NM_002998 // SDC2 // syndecan 2 // 8q22-q23 // 6383 /// ENST00000302190 // SDC2 NM_002998 −2.26 AML down vs POOL DONORS
CPA4 NM_016352 // CPA4 // carboxypeptidase A4 // 7q32 // 51200 /// NM_001163446 // CP NM_016352 −2.28 AML down vs POOL DONORS
CD9 NM_001769 // CD9 // CD9 molecule // 12p13.3 // 928 /// ENST00000382518 // CD9 // NM_001769 −2.30 AML down vs POOL DONORS
DAPK1 NM_004938 // DAPK1 // death-associated protein kinase 1 // 9q34.1 // 1612 /// EN NM_004938 −2.32 AML down vs POOL DONORS
SLC22A15 NM_018420 // SLC22A15 // solute carrier family 22, member 15 // 1p13.1 // 55356 NM_018420 −2.33 AML down vs POOL DONORS
HAUS6 NM_017645 // HAUS6 // HAUS augmin-like complex, subunit 6 // 9p22.1 // 54801 /// NM_017645 −2.40 AML down vs POOL DONORS
BMP4 NM_001202 // BMP4 // bone morphogenetic protein 4 // 14q22-q23 // 652 /// NM_130 NM_001202 −2.50 AML down vs POOL DONORS
JAKMIP2 NM_014790 // JAKMIP2 // janus kinase and microtubule interacting protein 2 // 5q NM_014790 −2.59 AML down vs POOL DONORS
NOV NM_002514 // NOV // nephroblastoma overexpressed gene // 8q24.1 // 4856 /// ENST NM_002514 −2.61 AML down vs POOL DONORS
ANO5 NM_213599 // ANO5 // anoctamin 5 // 11p14.3 // 203859 /// NM_001142649 // ANO5 / NM_213599 −2.64 AML down vs POOL DONORS
SNCA NM_000345 // SNCA // synuclein, alpha (non A4 component of amyloid precursor) // NM_000345 −2.66 AML down vs POOL DONORS
PRSS12 NM_003619 // PRSS12 // protease, serine, 12 (neurotrypsin, motopsin) // 4q28.1 / NM_003619 −2.81 AML down vs POOL DONORS
CPE NM_001873 // CPE // carboxypeptidase E // 4q32.3 // 1363 /// ENST00000402744 // NM_001873 −2.82 AML down vs POOL DONORS
GALNT3 NM_004482 // GALNT3 // UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylga NM_004482 −2.89 AML down vs POOL DONORS
SCN9A NM_002977 // SCN9A // sodium channel, voltage-gated, type IX, alpha subunit // 2 NM_002977 −2.91 AML down vs POOL DONORS
IGF2BP3 NM_006547 // IGF2BP3 // insulin-like growth factor 2 mRNA binding protein 3 // 7 NM_006547 −2.94 AML down vs POOL DONORS
AHNAK2 NM_138420 // AHNAK2 // AHNAK nucleoprotein 2 // 14q32.33 // 113146 /// ENST00000 NM_138420 −3.06 AML down vs POOL DONORS
SCIN NM_001112706 // SCIN // scinderin // 7p21.3 // 85477 /// NM_033128 // SCIN // sc NM_001112706 −3.25 AML down vs POOL DONORS
TM4SF20 NM_024795 // TM4SF20 // transmembrane 4 L six family member 20 // 2q36.3 // 7985 NM_024795 −3.27 AML down vs POOL DONORS
CLDN1 NM_021101 // CLDN1 // claudin 1 // 3q28-q29 // 9076 /// ENST00000295522 // CLDN1 NM_021101 −3.34 AML down vs POOL DONORS
DMKN NM_001126056 // DMKN // dermokine // 19q13.12 // 93099 /// NM_001190347 // DMKN NM_001126056 −3.41 AML down vs POOL DONORS
FRMD4B NM_015123 // FRMD4B // FERM domain containing 4B // 3p14.1 // 23150 /// ENST0000 NM_015123 −3.43 AML down vs POOL DONORS
FBN2 NM_001999 // FBN2 // ﬁbrillin 2 // 5q23-q31 // 2201 /// ENST00000262464 // FBN2 NM_001999 −3.52 AML down vs POOL DONORS
S100A4 NM_019554 // S100A4 // S100 calcium binding protein A4 // 1q21 // 6275 /// NM_00 NM_019554 −3.87 AML down vs POOL DONORS
CMKLR1 NM_001142343 // CMKLR1 // chemokine-like receptor 1 // 12q24.1 // 1240 /// NM_00 NM_001142343 −4.07 AML down vs POOL DONORS
LPCAT2 NM_017839 // LPCAT2 // lysophosphatidylcholine acyltransferase 2 // 16q12.2 // 5 NM_017839 −4.41 AML down vs POOL DONORS
MAMDC2 NM_153267 // MAMDC2 // MAM domain containing 2 // 9q21.12 // 256691 /// ENST0000 NM_153267 −5.02 AML down vs POOL DONORS
FLG NM_002016 // FLG // ﬁlaggrin // 1q21.3 // 2312 /// ENST00000368799 // FLG // ﬁ NM_002016 −5.33 AML down vs POOL DONORS
SPP1 NM_001040058 // SPP1 // secreted phosphoprotein 1 // 4q22.1 // 6696 /// NM_00058 NM_001040058 −5.95 AML down vs POOL DONORS
C20orf103 NM_012261 // C20orf103 // chromosome 20 open reading frame 103 // 20p12 // 24141 NM_012261 −6.11 AML down vs POOL DONORS
CD24 NM_013230 // CD24 // CD24 molecule // 6q21 // 100133941 /// BC064619 // CD24 // NM_013230 −7.58 AML down vs POOL DONORS
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Osteogenic cells are an important component of the BM microen-
vironment and have an essential role in regulating normal
hematopoiesis [27,28]. Disruption of the osteoblastic compart-
ment results in aberrant hematopoiesis [29]. Thus, unsurprisingly,
we found a decrease in osteogenic differentiation potential, which
is consistent with the study by Chandran et al. [26] that described
a reduced capability of hMSC-AML to support hematopoietic pro-
genitors in the culture. Moreover, studies of hMSCs from patients
with myelodysplastic syndrome also found a signiﬁcantly reduced
osteogenic differentiation potential and associated this ﬁnding with
a reduced ability of MSCs to support CD34+ [30].
To better understand hMSCs-AML, we characterized these cells.
The molecular proﬁle of these cells revealed that the 55 differen-
tially expressed genes identiﬁed in comparison to hMSCs-HD were
able to differentiate hMSCs-AML from hMSCs-HD, suggesting a spe-
ciﬁc hMSCs-AML molecular signature. After RT-qPCR and
unsupervised chip array conﬁrmation, the results conﬁrmed a mo-
lecular signature that is capable of distinguishing hMSCs from AML
patients from hMSCs from healthy donors. Because we used hMSCs
from patient samples at diagnosis, this molecular signature could
be an important marker to identify AML patients.
In silico analysis with the 55 differentially expressed genes showed
important signaling pathways that could be related to the main-
tenance and differentiation of HSCs, and alterations in these pathways
could inﬂuence the leukemogenic process. The osteopontin (SSP1)
pathway is important for HSC maintenance. SSP1 regulates the
number of HSCs in the bonemarrow niche and is an important factor
in osteoclast activation [15]. For optimal functioning of the bone
marrow, a balance between the number of osteoblasts and osteo-
clasts is necessary because these cells are responsible for bone
formation and resorption.
The other important pathway related to the differentially ex-
pressed genes identiﬁed in this work is the WNT pathway, which
has been related to HSC differentiation. In this study, the WNT
pathway could regulate BMP4 expression. BMP4 is a protein se-
creted into the bone marrow microenvironment, and decreased
BMP4 expression may result a disruption of HSC function [20].
Both SSP1 and BMP4, which were identiﬁed in our chip array
assay, as well as CCL2, are secreted proteins. Thus, if their differ-
ential expression could affect the bone marrowmicroenvironment,
their expression should be altered in the bone marrow plasma
samples of AML patients. ELISAs using the bone marrow plasma
samples from AML patients and from HD conﬁrmed our hypothe-
sis regarding BMP4 and CCL2 proteins. BMP4 and CCL2 were
decreased and increased, respectively, in AML bone marrow plasma
samples. However, SSP1 protein expression in AML bone marrow
plasma samples was identical to that for HD bone marrow plasma
samples. This could be due to the expression and secretion of SSP1
by other cell types as osteoblasts, osteoclasts, macrophages, T-cells
present in healthy bone marrow environment [31,32].
Otherwise, the decreased expression of BMP4 was unexpected
as BMP4 is a member of the TGF-β super family that regulates pro-
liferation, differentiation, cellular survival and cell fate determination.
It has been described as a critical component for normal hemato-
poietic microenvironment that regulates both HSCs number and
function and is necessary to maintain functional adult HSCs in vivo
Fig. 4. RT-qPCR to validate the chip array assay results. To conﬁrm the obtained chip array results, RT-qPCR was used to analyze some differentially expressed genes using
a larger number of patient samples to determine changes in mRNA expression levels after normalization to B2M and GAPDH (19 hMSC-AML cultures and 13 hMSC-HD cul-
tures). RT-qPCR analyses of CCL2 (A) and SPON2 (B) (overexpressed in AML patients) and BMP4 (C), CLDN1 (D), MMP16 (E) and SSP1 (F) (downregulated in AML patients)
conﬁrmed the chip array assay results and the common molecular signature for hMSCs from all AML patients instead of different molecular signatures for each AML subtype.
*p < 0.05; **p < 0.01.
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[22]. Deﬁciency of BMP4 in microenvironment impairs the func-
tional activity of normal HSCs. However, BMP4 decreased expression
in both hMSCs from AML patients and AML bone marrow plasma
could be related to decreased osteogenesis as BMP signaling pathway
is involved in the induction of osteogenic differentiation. So, in the
LSCs endosteal niche, it is possible that less cells of the osteogenic
lineage are present and that the imbalance between osteoblasts and
osteoclast creates a more appropriate niche for LSCs proliferation.
Another secreted protein found deregulated was CCL2. This
protein is a cytokine present in the IL-17 signaling pathways that
is involved in autoimmune disease, inﬂammatory processes and the
tumor microenvironment [18].
The inﬂammation in microenvironment has been reported to
support tumorigenesis and cancer progression by production of
several factors such as growth factors, pro-angiogenic and surviv-
al factors [33]. Several works have demonstrated that IL-17, the pro-
inﬂammatory cytokine produced by Th17 cells, can promote tumor
growth by enhancing angiogenesis, proliferation, migration and che-
moresistance of tumor cells. Also in AML, the expression of IL-17
has been associated with a poor prognostic [34–37].
High levels of CCL2 can contribute to high monocytes migra-
tion enhancing the inﬂammation and can stimulate the production
of pro-angiogenic mediators as VEGF [9]. Interestingly, in our chip
array results, we found that both VEGFA and VEGFB upregulated in
hMSCs from AML patients (1,16- and 1,22-fold change, respective-
ly – data not shown).
Increased levels of CCL2 have been previously reported in serum
samples from patients with AML [38], and other studies have found
that leukemia cells alter the proﬁles of cytokines produced byMSCs.
These studies demonstrated that enhanced CCL2 expression inhib-
its normal progenitors but not leukemic cells and improves the
survival of these cells [39,40].
In conclusion, the current study suggested a common molecu-
lar signature for hMSCs-AML instead of differentmolecular signatures
for each AML subtype. This signature is capable of differentiating
between hMSC-AML and hMSC-HD. Moreover, changes in the ex-
pression of plasma proteins suggested that hMSCs-AML signaling
alterations could be an important factor in the leukemic transfor-
mation process. Changes in hMSCs-AML couldmake the environment
permissive for leukemic transformation. hMSCs-AML could collab-
orate to create a nichemore favorable for leukemia cells and promote
leukemia maintenance.
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